AVI-7288: Phase I start

AVI BioPharma said it received approval from FDA to begin preclinical and Phase I testing of AVI-7288, the active component of the company's AVI-6003. AVI BioPharma will discontinue development of AVI-6003 after the compound's second component, AVI-7287, did not show efficacy in studies. AVI BioPharma plans to begin a double-blind, placebo-controlled Phase I trial to evaluate multiple ascending-doses of AVI-7288 alone in healthy volunteers. The company did not disclose a timeline for the start. ...